Oct 29 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP RECEIVES POSITIVE EMA SCIENTIFIC ADVICE FOR FURTHER CLINICAL DEVELOPMENT OF EFTI IN MBC INCLUDING PHASE III
- IMMUTEP LTD - POSITIVE FEEDBACK FOR GENERAL CLINICAL DEVELOPMENT PROGRAM INCLUDING PLANNED REGISTRATIONAL PHASE III TRIAL IN METASTATIC BREAST CANCER
- IMMUTEP LTD - OTHER REGULATORY ENGAGEMENT ONGOING, INCLUDING WITH US FOOD AND DRUG ADMINISTRATION
News: IMM Immutep Receives Positive EMA Scientific Advice For Further Clinical Development Of EFTI...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 307462 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 118494 | 4 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |